Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
Adjuvant radiotherapy
IORT
Intraoperative radiotherapy
Local tumor control
Surgery for brain metastases
Survival
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
06
04
2023
accepted:
20
06
2023
medline:
29
8
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Intraoperative radiation therapy (IORT) is an emerging alternative to adjuvant stereotactic external beam radiation therapy (EBRT) following resection of brain metastases (BM). Advantages of IORT include an instant prevention of tumor regrowth, optimized dose-sparing of adjacent healthy brain tissue and immediate completion of BM treatment, allowing an earlier admission to subsequent systemic treatments. However, prospective outcome data are limited. We sought to assess long-term outcome of IORT in comparison to EBRT. A total of 35 consecutive patients, prospectively recruited within a study registry, who received IORT following BM resection at a single neuro-oncological center were evaluated for radiation necrosis (RN) incidence rates, local control rates (LCR), distant brain progression (DBP) and overall survival (OS) as long-term outcome parameters. The 1 year-estimated OS and survival rates were compared in a balanced comparative matched-pair analysis to those of our institutional database, encompassing 388 consecutive patients who underwent adjuvant EBRT after BM resection. The median IORT dose was 30 Gy prescribed to the applicator surface. A 2.9% RN rate was observed. The estimated 1 year-LCR was 97.1% and the 1 year-DBP-free survival 73.5%. Median time to DBP was 6.4 (range 1.7-24) months in the subgroup of patients experiencing intracerebral progression. The median OS was 17.5 (0.5-not reached) months with a 1 year-survival rate of 61.3%, which did not not significantly differ from the comparative cohort (p = 0.55 and p = 0.82, respectively). IORT is a safe and effective fast-track approach following BM resection, with comparable long-term outcomes as adjuvant EBRT.
Identifiants
pubmed: 37477822
doi: 10.1007/s11060-023-04380-w
pii: 10.1007/s11060-023-04380-w
pmc: PMC10462513
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-116Informations de copyright
© 2023. The Author(s).
Références
J Neurooncol. 2009 Jan;91(1):83-93
pubmed: 18719856
J Neurooncol. 2021 Jul;153(3):479-485
pubmed: 34115248
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1142-8
pubmed: 27209508
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1059-1068
pubmed: 28721889
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
J Neurooncol. 1993 Sep;17(3):253-60
pubmed: 8164061
Cancers (Basel). 2022 Dec 20;15(1):
pubmed: 36612015
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Neurosurgery. 2019 Jan 1;84(1):41-49
pubmed: 29528443
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):181-6
pubmed: 17768015
Neurosurgery. 2008 Feb;62 Suppl 2:776-84
pubmed: 18596428
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1399-405
pubmed: 22209155
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
J Clin Oncol. 2019 Nov 20;37(33):3132-3141
pubmed: 31553661
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142701
J Neurooncol. 2019 Jul;143(3):537-546
pubmed: 31073966
Cancers (Basel). 2022 Mar 16;14(6):
pubmed: 35326666
J Neurosurg. 2017 Jun;126(6):1749-1755
pubmed: 27367240
Radiother Oncol. 2020 Jan;142:162-167
pubmed: 31629553
J Neurooncol. 2019 Nov;145(2):391-397
pubmed: 31654248
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
Acta Neurochir (Wien). 1989;99(3-4):104-8
pubmed: 2549766
Int J Mol Sci. 2013 Apr 24;14(5):8708-18
pubmed: 23615466
Front Oncol. 2021 Jul 26;11:713965
pubmed: 34381733
Brachytherapy. 2021 Mar-Apr;20(2):426-432
pubmed: 33454200
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Neurooncol. 2023 Feb;161(3):539-545
pubmed: 36695975
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33
pubmed: 22981707
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
Front Oncol. 2022 Dec 15;12:1005876
pubmed: 36591479
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Front Oncol. 2021 Oct 28;11:759873
pubmed: 34778080
J Clin Oncol. 2013 Jan 1;31(1):65-72
pubmed: 23213105
JAMA Oncol. 2020 Dec 01;6(12):1901-1909
pubmed: 33057566
Neuro Oncol. 2012 Sep;14(9):1171-7
pubmed: 22898372
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):710-7
pubmed: 25752382
Strahlenther Onkol. 2021 Dec;197(12):1124-1130
pubmed: 34415358
Front Surg. 2022 Dec 26;9:1071804
pubmed: 36632525
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Neurosurg Rev. 2023 Mar 30;46(1):80
pubmed: 36997703
Curr Oncol. 2023 Jan 17;30(2):1300-1313
pubmed: 36826062
J Neurosurg. 2018 Apr 20;130(3):797-803
pubmed: 29676690
Radiat Oncol. 2017 Jan 19;12(1):24
pubmed: 28107823
Cancer Radiother. 2017 Feb;21(1):4-9
pubmed: 27955888
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):618-630
pubmed: 30395902
Radiat Oncol. 2022 May 12;17(1):92
pubmed: 35551618
Cancers (Basel). 2022 Sep 24;14(19):
pubmed: 36230556
J Neurosurg. 2022 Sep 16;138(5):1178-1187
pubmed: 36115055
BMC Med Inform Decis Mak. 2013 Jul 19;13:72
pubmed: 23870327